--- schema_version: "secwatch.filing_event.v1" accession: "0000885725-26-000017" form_type: "8-K" ticker: "BSX" cik: "0000885725" company_name: "BOSTON SCIENTIFIC CORP" filed_at: "2026-02-26T23:59:59+00:00" generated_at: "2026-05-15T23:58:55.744773+00:00" event_type: "debt" sentiment: "positive" materiality_score: 0.8 calibrated_materiality_score: 0.8 confidence: "high" source: SEC EDGAR --- # Boston Scientific enters $11B credit facilities; $8B committed for Penumbra acquisition ## Summary - $3.0B revolving credit agreement matures Feb 2031 with two one-year extension options. - $2.0B 364-day revolving credit agreement tied to Penumbra acquisition; matures 364 days post-close. - $6.0B term loan agreement: $1B Tranche A and $5B Tranche B, both 364-day delayed draw at closing. - Tranche B Loans must be prepaid with net proceeds from equity or debt issuance after closing. - Prior $3.0B 2021 revolving credit agreement terminated upon entry into the new facilities. ## SEC filing metadata - accession: 0000885725-26-000017 - form_type: 8-K - ticker: BSX - cik: 0000885725 - company_name: BOSTON SCIENTIFIC CORP - filed_at: 2026-02-26T23:59:59+00:00 - event_type: debt - sentiment: positive - materiality_score: 0.8 - calibrated_materiality_score: 0.8 - confidence: high - sec_items: 1.01, 1.02, 2.03, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572526000017/0000885725-26-000017-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572526000017/bsx-20260226.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0000885725-26-000017 - JSON: https://secwatch.observer/filing/0000885725-26-000017.json - Plain text: https://secwatch.observer/filing/0000885725-26-000017.txt ## Source-grounded claims - claim_id: 6b02d2bb1d4041edb26beea72b50e2b1cd37e5e9 claim: BOSTON SCIENTIFIC CORP incurred revolving credit of $2.000 billion with Wells Fargo Bank, National Association at Term SOFR determined for the interest period plus the applicable margin based on maturing the date that is 364 days from the earlier of (i) the date that any loans under the 364-Day Revolving Credit Agreement are available to be drawn on, or (ii) the. evidence_excerpt: On February 26, 2026, the Company entered into a $2.000 billion 364-day revolving credit agreement (the “ 364-Day Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. evidence_url: https://www.sec.gov/Archives/edgar/data/885725/000088572526000017/0000885725-26-000017-index.htm - claim_id: b2b72c8d064bd3714f2906972843af0af86794a1 claim: BOSTON SCIENTIFIC CORP incurred term loan of up to $1.000 billion with Wells Fargo Bank, National Association maturing 364-day delayed draw. evidence_excerpt: by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. Under the Term Loan Credit Agreement, the Company may borrow (i) a 364-day delayed draw term loan in an aggregate principal amount of up to $1.000 billion evidence_url: https://www.sec.gov/Archives/edgar/data/885725/000088572526000017/0000885725-26-000017-index.htm - claim_id: f23861177ed910752b79ccd99339eb73507b1df9 claim: BOSTON SCIENTIFIC CORP incurred revolving credit of $3.000 billion with Wells Fargo Bank, National Association at Term SOFR determined for the interest period plus the applicable margin based on maturing February 26, 2031. evidence_excerpt: On February 26, 2026, Boston Scientific Corporation (the “ Company ”) entered into a $3.000 billion revolving credit agreement (the “ 2026 Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. evidence_url: https://www.sec.gov/Archives/edgar/data/885725/000088572526000017/0000885725-26-000017-index.htm - claim_id: 21aa53e153eb94742e70c9f054af419686f8d145 claim: BOSTON SCIENTIFIC CORP entered into 364-Day Revolving Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto valued at $2.000 billion (effective 2026-02-26). evidence_excerpt: On February 26, 2026, the Company entered into a $2.000 billion 364-day revolving credit agreement (the “ 364-Day Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. evidence_url: https://www.sec.gov/Archives/edgar/data/885725/000088572526000017/0000885725-26-000017-index.htm - claim_id: cba15c69bc86aed9a8628112bb3638d7b70f3907 claim: BOSTON SCIENTIFIC CORP entered into 2026 Revolving Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto valued at $3.000 billion (effective 2026-02-26). evidence_excerpt: On February 26, 2026, Boston Scientific Corporation (the “ Company ”) entered into a $3.000 billion revolving credit agreement (the “ 2026 Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. evidence_url: https://www.sec.gov/Archives/edgar/data/885725/000088572526000017/0000885725-26-000017-index.htm - claim_id: de86295b027db259ccec970b085f612a8d04903d claim: BOSTON SCIENTIFIC CORP entered into Term Loan Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the several lenders party thereto valued at $6.000 billion (effective 2026-02-26). evidence_excerpt: On February 26, 2026, the Company entered into a $6.000 billion term loan credit agreement (the “ Term Loan Credit Agreement ” and together with the 2026 Revolving Credit Agreement and the 364-Day Revolving Credit Agreement, the “ 2026 Credit Agreements ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. evidence_url: https://www.sec.gov/Archives/edgar/data/885725/000088572526000017/0000885725-26-000017-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.